


PETITION RULE PRM 35-9

(54FR 38239) November 20, 1989

2900 RICHMOND HOUSTON, TEXAS 77098 PHONE: 520-SCAN 520-7226

Secretary of the Commission U.S. Nuclear Regulatory Commission Docketing and Service Branch, Docket # PRM-35-9 Washington, DC 20555

Dear Mr. Secretary:



The NRC should recognize that the FDA does allow, and often encourages, other clinical uses of approved drugs, and actively discourages the submission of physician-sponsered IND's that describe new indications for approved drugs. The package insert was never intended to prohibit physicians from deviationg from it for other indications; on the contrary, such deviation is necessary for growth in developing new diagnostic and therapeutic procedures. In many cases, manufacturers will never go back to the FDA to revise the package insert to include a new indication because it is not required by the FDA and there is simply no economic incentive to do so.

Currently, the regulatory provisions in Part 35 (35.100, 35.200, 35.300, and 33.17(a)(4)) do not allow practices which are legitimate and legal under FDA regulations and State medicine and pharmacy laws. These regulations therefore inappropriately interfere with the practice of medicine, which directly contradicts the NRC's Medical Policy statement against such interference.

Finally, I would like to point out that highly restricitive NRC regulations will only jeopardize public health and safety by: restricting access to appropriate Nuclear Medicine procedures; exposing patients to higher radiation absorbed doses from alternative legal, but non-optimal, studies; and exposing hospital personnel to higher radiation absorbed doses because of unwarranted, repetitive procedures. The NRC should not strive to construct proscriptive regulations to cover all aspects of medicine, nor should it attempt to regulate radiopharmaceutical use. Instead, the NRC should rely on the expertise of the FDA, State Boards of Pharmacy, State Boards of Medical Quality Assurance, the Joint Commission on Accreditation of Healthcare Organizations, radiation safety committees, institutional Q/A review procedures, and most importantly, the professional judgement of physicians and pharmacists who have been well trained to administer and prepare these materials.

8911290360 891120 PDR PRM PDR P510



2900 RICHMOND HOUSTON, TEXAS 77098 PHONE: 520-SCAN 520-7226

Since the NRC's primary regulatory focus appears to be based on the unsubstantiated assumption that misadministrations, particularly those involving diagnostic radiopharmaceuticals, pose a serious threat to the public health and safety, I strongly urge the NRC to pursue a comprehensive study by a reputable scientific panel, such as the National Academy of Sciences or the NCRP, to access the radiobiological effects of misadministrations from Nuclear Medicine diagnostic and therapeutic studies. I firmly believe that the results from such a study will demonstrate that the NRC's efforts to impose more and more stringent regulations are unnecessary and not cost-effective in a relation to the extremely low health risks of these studies.

In closing, I strongly urge the NRC to adopt the ACNP/SNM Petition for Rulemaking as expeditiously as possible.

Sincerely,

Janet L. Grace, CNMT, RI(N), AS Chief Nuclear Medicine Technologist

JLG: rwg